Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Aveva Drug Delivery systems (A DifGen company), a leader in transdermal drug delivery systems based out of Miramar - Florida is proud to announce the launch of all strengths of its generic Fentanyl ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Researchers have found in a phase 3 trials that Dupilumab significantly reduced moderate or severe COPD exacerbations ...

Time Kalyan Air Quality Index (AQI) and Air Pollution Forecast on IndiaToday Online - Stay updates about Air Quality in ...

Patients who were taking lipid-lowering medications experienced more severe anaphylaxis after insect stings, according to an ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...